Bertrand Bodson, chief digital officer at Novartis AG (NYSE:NVS; SIX:NOVN), will step down from the pharma’s executive committee on Feb. 1. Bodson took on the newly created role at Novartis in January 2018 to integrate new...

The migration of new modalities into prevalent indications took another step forward on Friday with the European Commission’s approval of Novartis’ siRNA therapy Leqvio inclisiran to treat hypercholesterolemia...

Bispecific antibodies are starting to diverge from CAR Ts as they venture into new targets and indications in the clinic.  First-generation T cell-engaging bispecific antibodies have mirrored the...

Former FDA commissioners Scott Gottlieb and Robert Califf tweeted their praise Tuesday of the appointment of two long-time FDA officials to head the agency’s communications.  Heidi Rebello will become FDA’s acting associate commissioner for external...

In the year’s largest licensing deal thus far, Blueprint has secured the resources it needs to sustain itself financially while gaining access to Roche’s diagnostic capabilities, a key driver for commercializing its targeted therapies for...

Patient death prompts Cellectis trial halt FDA placed a clinical hold on an allogeneic CAR T therapy trial to treat multiple myeloma from Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) after a patient who received the second-level dose...

Ayala’s public debut late Thursday adds to the more than $4 billion raised from global biopharma IPOs so far this year. This year is outpacing 2019 for total funds raised in IPOs even as investors...

With the first three investments from a new fund launched in partnership with Italian charity Fondazione Telethon to invest in therapies for rare genetic diseases, Sofinnova Partners is aiming to build and expand the country’s...

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the...